Table 1: Antiviral activity and cytotoxicity of naphthoimidazole derivatives (3a-j), derivative A [28] was reported for comparison; NM 108 and ribavirin were used as positive controls.
| Compound |
MDBK (aCC50) |
BVDV (bEC50) |
| 3a |
37.5±3.5 |
16.2±2.6 |
| 3b |
11.6 |
>11.6 |
| 3c |
>100 |
>100 |
| 3d |
>100 |
>100 |
| 3e |
11.8 |
>11.8 |
| 3f |
2.8 |
>2.8 |
| 3g |
>100 |
>100 |
| 3h |
4.7 |
>4.7 |
| 3i |
>100 |
>100 |
| 3j |
>100 |
>100 |
| A |
>100 |
0.3 |
| NM 108 |
>100 |
1.5±0.2 |
| Ribavirin |
>100 |
18±2 |
aCompound concentration (µM) required to reduce the viability of mock-infected MDBK cells by 50%, as determined by the MTT method.
bCompound concentration (µM) required to achieve 50% protection of MDBK cells from the BVDV-induced cytopathogenicity, as determined by the MTT method.